29.77

3.44% 0.99

Sutro Biopharma Inc (STRO)

Overview News Price History Option Chain Financials Discussions Forecast

Sutro Biopharma Inc stock is traded at $29.77, with a volume of 315.50K. It is up +3.44% in the last 24 hours and up +28.99% over the past month. Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Previous Close:

$28.78

Open:

$28.88

24h Volume:

315.50K

Relative Volume:

1.79

Market Cap:

$493.21M

Revenue:

$102.48M

Net Income/Loss:

$-191.09M

P/E Ratio:

-2.0645

EPS:

-14.4203

Net Cash Flow:

$-178.93M

1W Performance:

+10.06%

1M Performance:

+28.99%

6M Performance:

+281.67%

1Y Performance:

+413.72%

1-Day Range:

$28.78

$30.50

1-Week Range:

$24.94

$30.50

52-Week Range:

$5.231

$30.50

Sutro Biopharma Inc Stock (STRO) Company Profile

Name

Sutro Biopharma Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

650-392-8412

Address

111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA

Employee

137

Twitter

@SutroBio

Next Earnings Date

2026-03-26

Latest SEC Filings

STRO's Discussions on Twitter

Compare STRO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STRO Sutro Biopharma Inc	29.77	476.81M	102.48M	-191.09M	-178.93M	-14.42
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-07-26	Initiated	Leerink Partners	Outperform
Mar-24-26	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-24-26	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-20-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Jun-16-25	Upgrade	Piper Sandler	Neutral → Overweight
Mar-17-25	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-14-25	Downgrade	BofA Securities	Buy → Underperform
Mar-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Downgrade	Wedbush	Outperform → Neutral
May-08-24	Initiated	BofA Securities	Buy
Nov-09-23	Initiated	Deutsche Bank	Buy
Oct-06-23	Initiated	Oppenheimer	Outperform
Mar-21-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Aug-18-22	Resumed	Wells Fargo	Overweight
Jun-18-21	Initiated	H.C. Wainwright	Buy
Dec-03-20	Initiated	Stifel	Buy
Sep-02-20	Initiated	Jefferies	Buy
Jul-16-20	Initiated	Wells Fargo	Overweight
Jan-13-20	Initiated	SunTrust	Buy
Oct-07-19	Initiated	BTIG Research	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
Apr-29-19	Initiated	H.C. Wainwright	Buy
Oct-22-18	Initiated	JMP Securities	Mkt Outperform
Oct-22-18	Initiated	Piper Jaffray	Overweight
Oct-22-18	Initiated	Wedbush	Outperform

View All

Sutro Biopharma Inc Stock (STRO) Latest News

Apr 15, 2026

Sutro Biopharma Hits New 52-Week High - National Today

Apr 15, 2026

Sutro Biopharma (NASDAQ:STRO) Reaches New 52-Week HighHere's What Happened - MarketBeat

Apr 15, 2026

Apr 13, 2026

Momentum Shift: Is Sutro Biopharma Inc benefiting from interest rate changes2026 Drop Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn

Apr 13, 2026

Sutro Biopharma (STRO) price target decreased by 21.62% to 29.58 - MSN

Apr 13, 2026

Apr 12, 2026

Sutro Biopharma Receives 'Moderate Buy' Rating from Analysts - National Today

Apr 12, 2026

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Apr 12, 2026

Apr 08, 2026